ClinicalTrials.gg

Program

MVA-SIBP low dose

Also written as “MVA-SIBP high dose”.

Its studies are mostly in Mpox, Monkeypox, led by Sinopharm.

Furthest: phase 2, since Nov 19, 20251 company-led study, 1 open or runningNext primary completion: Feb 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinopharm11 open or runningphase 2since Nov 19, 2025Nov 19, 2025Feb 28, 2027phase 2 · NCT07253675

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2025First study: phase 2 study in Mpox, MonkeypoxFirst studyNCT07253675 · 180 planned

Ahead

  1. Feb 28, 2027Primary completion: phase 2 study in Mpox, MonkeypoxNCT07253675

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07253675Mpox, Monkeypox2Not yet recruitingFeb 28, 2027180

How it is read

Names in the registry

  • “MVA-SIBP low dose”, 1 entry
  • “MVA-SIBP high dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
MVA-SIBP low dose (Sinopharm): development program | ClinicalTrials.gg